Our Early Clinical Development (ECD) group in Oncology is seeking a talented physician scientist to join our Cancer Immunotherapy development team to translate our preclinical discoveries into the next generation of cancer immunotherapies for patients. The group conducts first-in-human Phase I and Phase II studies with novel agents against a variety of immunotherapy targets with a strong focus on mechanism-based biomarkers, seeking the next generation of therapies that will benefit patients. This position will lead a development team that is studying a novel cancer immunotherapy target as a single-agent and in combination with other immunotherapy agents in multiple solid tumors and hematological malignancies. This role will lead the design, execution, monitoring, analysis, and reporting of innovative Phase I/II clinical studies, with an initial focus on cancer immunology and novel immune-modulating agents, including studies of rational scientific combinations. Eventual opportunities to lead the development of other novel targets within our extensive oncology portfolio are also anticipated. This physician scientist will provide leadership for internal cross-functional teams in the clinical development of a novel immunotherapy target and will be the primary point of contact for communicating with external global oncology leaders, clinical investigators, and scientists. The position will work directly with research scientists in the Cancer Immunology Research group and the Oncology Biomarker Development group, and may also work with the Company Partnering group on in-licensing opportunities in cancer immunotherapy. This impactful role will design and conduct efficient, interpretable clinical studies and programs that address exciting, high priority questions in oncology and cancer immunotherapy that are supported by Company’s outstanding commitment to fundamental cancer research, its scientific leadership in cancer immunology, and its vibrant patient-oriented culture.